

Edgar Filing: CYTOGEN CORP - Form 424B2

CYTOGEN CORP
Form 424B2
June 04, 2002

Filed Pursuant to Rule 424(b)(2)
File No. 333-72226

CYTOGEN CORPORATION

Prospectus Supplement No. 2 dated June 4, 2002,
to the Prospectus dated October 25, 2001, as supplemented by
Prospectus Supplement No. 1 dated January 22, 2002

10,000,000 SHARES
OF
COMMON STOCK

We are selling 4,166,700 shares of our common stock with this prospectus supplement and the accompanying prospectus, as previously supplemented, at a purchase price of \$1.20 per share, for aggregate proceeds to us of approximately \$5.0 million.

You should read this prospectus supplement along with the accompanying prospectus, as previously supplemented. These documents contain information you should consider when making your investment decision. You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, as previously supplemented. We have not authorized anyone else to provide you with different or additional information. The last reported sale of our common stock on June 3, 2002 was \$1.00 per share. Our common stock is listed for trading on the Nasdaq National Market under the symbol "CYTO."

This prospectus supplement and the accompanying prospectus, as previously supplemented, do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the common stock offered hereby. This prospectus supplement and the accompanying prospectus, as previously supplemented, do not constitute an offer to sell or a solicitation of an offer to buy our common stock in any circumstances in which an offer or solicitation is unlawful.

Information in this prospectus supplement and the accompanying prospectus, as previously supplemented, may change after the date on the front of the applicable document. You should not interpret the delivery of this prospectus supplement or the accompanying prospectus, as previously supplemented, or the sale of the common stock as an indication that there has been no change in our affairs since such dates.

Our principal executive offices are located at 600 College Road East, Princeton, New Jersey 08540. Our telephone number is (609) 750-8200.

Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 4 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

Edgar Filing: CYTOGEN CORP - Form 424B2

The date of this prospectus supplement is June 4, 2002.

TABLE OF CONTENTS	PAGE
Prospectus Supplement	
Use Of Proceeds	S-2
Plan Of Distribution	S-2
Market For Our Common Stock	S-2
Information Incorporated By Reference	S-2
Forward-Looking Statements	S-2
Prospectus	
About This Prospectus	2
Cytogen Corporation	3
Risk Factors	4
Forward-Looking Statements	20
Use Of Proceeds	21
Plan Of Distribution	22
Legal Matters	23
Experts	23
Where You Can Find More Information	23
Information Incorporated By Reference	23
Indemnification Of Directors And Officers	24

S-1

USE OF PROCEEDS

We will use the net proceeds of this offering of our common stock for general corporate purposes, including, principally, working capital and capital expenditures.

PLAN OF DISTRIBUTION

On January 18, 2002, we issued and sold 2,970,665 shares of our common stock pursuant to a prospectus supplement dated January 22, 2002 to the prospectus dated October 25, 2001, which is part of our Registration Statement on Form S-3 (File No. 333-72226).

We are offering an additional 4,166,700 shares of our common stock to the State of Wisconsin Investment Board pursuant to this second prospectus supplement. The common stock will be purchased at a price of \$1.20 per share, for aggregate proceeds to us of \$5,000,000. The last reported sale of our common stock on June 3, 2002 was \$1.00.

We issued the shares of common stock described in this prospectus supplement directly to the State of Wisconsin Investment Board in a negotiated transaction in which no party is acting as an underwriter or receiving any finder's or placement fees. Prior to this issuance, the State of Wisconsin Investment Board held, and continues to hold, the largest number of shares of common stock of any of our stockholders.

Upon sale under the registration statement that includes this

Edgar Filing: CYTOGEN CORP - Form 424B2

prospectus supplement, the securities registered by such registration statement and this prospectus supplement will be freely tradable in the hands of persons other than our affiliates.

MARKET FOR OUR COMMON STOCK

Our common stock is listed on the Nasdaq National Market under the symbol "CYTO." On June 3, 2002, the closing price of one share of our common stock was \$1.00. The common stock sold under this prospectus supplement will be listed on the Nasdaq National Market. As of May 1, 2002, we had 82,513,215 shares of common stock outstanding.

INFORMATION INCORPORATED BY REFERENCE

Those documents set forth under the heading Information Incorporated By Reference in the accompanying prospectus and any other prospectus supplements thereto, are incorporated herein by reference.

FORWARD-LOOKING STATEMENTS

This prospectus supplement includes or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated in this prospectus supplement regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify

S-2

forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included with or incorporated in this prospectus supplement, particularly under the heading "Risk Factors" in the accompanying prospectus, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements.

You should not unduly rely on forward-looking statements contained or incorporated by reference in this prospectus supplement. Actual results or outcomes may differ materially from those predicted in our forward-looking statements due to the risks and uncertainties inherent in our business.

S-3